Literature DB >> 3701643

Pharmacokinetics of melphalan in isolated perfusion of the limbs.

C Benckhuijsen, F J Varossieau, A A Hart, J Wieberdink, J Noordhoek.   

Abstract

The pharmacokinetics of melphalan (L-phenylalanine mustard) in isolated perfusion treatment of patients with melanoma in the limbs have been studied at standardized pseudo-physiological perfusion conditions. Perfused tissue volumes ranged from 2.1 to 16 liters as measured by water displacement. A fixed dose of 10 mg of the drug per liter of perfused tissue was applied. The resulting variation in total melphalan dosage gave rise to varying drug concentrations in the perfusate as the extracorporeal system was operated with a fixed volume of priming fluid. Perfusion with melphalan was applied for 60 min. Concentrations of intact drug were assayed by high-performance liquid chromatography. The melphalan concentrations vs. time for each patient were fitted to a biexponential equation using a nonlinear least-squares computer program. Mean half-lives of 4.7 +/- 0.3 and 53.0 +/- 1.6 min were obtained for the alpha and beta phase, respectively. The hybrid constant alpha remained virtually constant with increasing dose (i.e., increasing drug concentration) and beta also appeared independent of dose levels. With increasing tissue volume plasma clearance was found to diminish per unit of tissue volume. This phenomenon, and a levelling off of the steady-state distribution volume with increasing volume of perfused tissue, are discussed in terms of a possibly restricted transfer of drug from intravascular to the extracellular space and of the possibility of saturation of cellular uptake systems in the bulk of the limb tissues.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3701643

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.

Authors:  J D Nagel; I Krüger; F Ghussen; U Bode
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Physiological pharmacokinetics of solutes in the isolated perfused rat hindlimb: characterization of the physiology with changing perfusate flow, protein content, and temperature using statistical moment analysis.

Authors:  Z Y Wu; L P Rivory; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

3.  Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.

Authors:  H F Rauschecker; H Foth; H C Michaelis; F Horst; W Gatzemeier; C Willenbrock; E Voth; G F Kahl
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

5.  Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

Authors:  J M Klaase; B B Kroon; J H Beijnen; G W van Slooten; J A van Dongen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

6.  The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.

Authors:  Z Y Wu; B M Smithers; P G Parsons; M S Roberts
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.